Simple qSOFA score predicts sepsis as well as anything else

Sepsis is sneaky. Physicians, nurses, and epidemiologists struggle to accurately identify patients with sepsis in the emergency department, hospital ward, and data sets. The so-called SIRS criteria were abandoned as insensitive and nonspecific in the most recent iteration of sepsis care. Sepsis is instead now defined as "life-threatening organ dysfunction caused by a dysregulated host [... read more]

The post Simple qSOFA score predicts sepsis as well as anything else appeared first on PulmCCM.

Oxygen saturation in critical illness: could low-normal be best?

Oxygen is essential for life, but by forming superoxides and free radicals, supplemental oxygen can also inflict damage on lung and other body tissues. The sweet spot for oxygen delivery in critically ill patients is unknown, but increasing evidence suggests that when it comes to blood oxygen saturation during critical illness, "normal" levels might actually [... read more]

The post Oxygen saturation in critical illness: could low-normal be best? appeared first on PulmCCM.

A Primer on the Perils of Intravenous Fluids – Part 2

Jon-Emile S. Kenny [@heart_lung] Read part 1 here Fluids and the Glycocaylx Critically-ill patients all likely have endothelial dysfunction to some degree.  This perturbation in microvascular physiology may be underpinned by abnormal glycocalyx structure and function.  Sepsis, trauma, surgery and ischemic insults are all known to disrupt the glycocalyx which will increase vascular fluid capacitance.  [... read more]

The post A Primer on the Perils of Intravenous Fluids – Part 2 appeared first on PulmCCM.

A Primer on the Perils of Intravenous Fluids – Part 1

Jon-Emile S. Kenny [@heart_lung] “To every (wo)man is given the key to the gates of heaven. The same key opens the gates of hell.  And so it is with science.” -Richard Feynman A rich, frosty wind etherizes my face; this cool gust rips through the medieval, labyrinthine passageways of Old Stockholm like frayed edges of [... read more]

The post A Primer on the Perils of Intravenous Fluids – Part 1 appeared first on PulmCCM.

Reslizumab (CINQAIR) worked as add-on treatment for severe asthma with eosinophilia

Reslizumab (CINQAIR) is a humanized, anti-IL-5 biologic agent approved by FDA in March 2016 as add-on treatment for asthma with peripheral blood eosinophilia, uncontrolled by usual treatments. In two randomized trials, reslizumab improved lung function and asthma symptoms in patients meeting these criteria. Patients without high eosinophil count in peripheral blood did not experience clinically [... read more]

The post Reslizumab (CINQAIR) worked as add-on treatment for severe asthma with eosinophilia appeared first on PulmCCM.